Empire Life Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-160,662	Closed	-$2.61M	–	97
2024 Q2	$2.61M	Sell	160,662 -9,173	-5%	-$148K	0.16%	70
2024 Q1	$3.14M	Sell	169,835 -4,980	-3%	-$123K	0.19%	64
2023 Q4	$5.47M	Buy	174,815 +467	+0.3%	+$11.2K	0.35%	59
2023 Q3	$3.63M	Sell	174,348 -2,714	-2%	-$73.7K	0.27%	60
2023 Q2	$4.24M	Sell	177,062 -461	-0.3%	-$10.2K	0.29%	59
2023 Q1	$3.34M	Buy	177,523 +1,682	+1%	+$32K	0.24%	62
2022 Q4	$2.8M	Sell	175,841 -2,011	-1%	-$31.4K	0.19%	65
2022 Q3	$2.91M	Buy	177,852 +5,930	+3%	+$96K	0.22%	64
2022 Q2	$2.42M	Buy	171,922 +3,301	+2%	+$61.6K	0.17%	65
2022 Q1	$4.08M	Buy	168,621 +345	+0.2%	+$8.35K	0.26%	64
2021 Q4	$3.93M	Buy	168,276 +323	+0.2%	+$6.5K	0.24%	66
2021 Q3	$2.79M	Buy	167,953 +1,988	+1%	+$38.3K	0.18%	69
2021 Q2	$4.05M	Buy	165,965 +5,147	+3%	+$116K	0.26%	67
2021 Q1	$4.15M	Buy	160,818 +107,772	+203%	+$4.74M	0.29%	68
2020 Q4	$2.84M	Buy	53,046 +22,520	+74%	+$1.12M	0.2%	74
2020 Q3	$1.26M	Buy	+30,526	New	+$1.32M	0.1%	79